Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Addressing the room for improvement in management of acute promyelocytic leukemia

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Danish Acute Leukemia Group
View graph of relations

Acute promyelocytic leukemia (APL) is highly curable. To achieve high cure rates, targeted therapy with retinoic acid (ATRA) must be started promptly at time of suspected diagnosis. Early death rates (EDRs, ≤30 days from diagnosis) differ markedly in patients treated on clinical trials compared to the general population.

OBJECTIVES AND METHODS: We used the comprehensive Danish National Acute Leukemia Registry (DNLR) to investigate the incidence, treatment, EDR, and long-term clinical outcome in APL between 2000 and 2014.

RESULTS: Twenty-two of 41 deaths occurring in 122 APL patients were EDs which were primarily caused by intracranial hemorrhage, disseminated intravascular coagulation (DIC), sepsis, and multiorgan failure. The overall EDR was 18.0%, whereas clinical trial participants had an EDR of 6.7%. Fifteen patients recruited to the NCRI AML17 APL trial from 2010 to 2013 were younger and had decreased mortality (HR 0.18, CI 0.04-0.86, P = 0.02) compared to contemporarily treated patients (n = 15) not recruited to a clinical trial. Performance status, leukemia origin, and Sanz-score were independent prognostic variables.

CONCLUSIONS: The very low EDR for on-trial patients is not observed in the general cohort of APL patients. Diagnostic awareness emerges as the greatest clinical challenge in management of APL.

Original languageEnglish
JournalEuropean Journal of Haematology
Issue number6
Pages (from-to)479-485
Number of pages7
Publication statusPublished - Jun 2019

    Research areas

  • Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Combined Modality Therapy, Denmark/epidemiology, Disease Management, Female, Humans, In Situ Hybridization, Fluorescence, Kaplan-Meier Estimate, Leukemia, Promyelocytic, Acute/diagnosis, Male, Middle Aged, Oncogene Proteins, Fusion/genetics, Proportional Hazards Models, Quality Improvement, Registries, Translocation, Genetic, Young Adult

ID: 58960200